NYSE:GKOSMedical Equipment
Glaukos (GKOS) Is Up 10.0% After Reaffirming 2026 Sales Guidance And Highlighting iDose TR Momentum
Glaukos Corporation recently reaffirmed its 2026 net sales guidance of US$600 million to US$620 million and released preliminary 2025 figures pointing to strong year-over-year growth across U.S. and international glaucoma and corneal health franchises, including meaningful contributions from its iDose TR therapy.
Investor commentary has underscored how accelerating revenue growth and FDA approval of the higher-priced Epioxa corneal health product may be reinforcing confidence in Glaukos’...